Phase II trial of Cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study.
Rembielak, Agata Jain, Pooja Jackson, Andrew Green, Matthew M L Santorelli, Gillian R Whitfield, Gillian A Crellin, A Garcia-Alonso, A Radhakrishna, G Cullen, James N
Rembielak, Agata
Jain, Pooja
Jackson, Andrew
Green, Matthew M L
Santorelli, Gillian R
Whitfield, Gillian A
Crellin, A
Garcia-Alonso, A
Radhakrishna, G
Cullen, James N
Citations
Altmetric:
Abstract
Preclinical data have indicated the anti-epidermal growth factor receptor (EGFR) agent cetuximab (Erbitux) as a radiosensitizer in pancreatic cancer, but this has not been specifically addressed in a clinical study. We report the results of an original study initiated in 2007, where cetuximab was tested with radiotherapy (RT) alone in locally advanced pancreatic cancer in a phase II trial (PACER).
Description
Date
2014-02
Publisher
Collections
Keywords
Type
Article
Citation
Phase II trial of Cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study. 2014, 7 (1):55-64 Transl Oncol